Skip to main content

Table 3 Covariate analysis of total cholesterol (TC), HDL-cholesterol (HDL), TC/HDL ratio, LDL-cholesterol (LDL), tryglicerides (TG) and Framingham risk score (FRS), according to confounding factors used in the multivariable analysis: all confounders and treatment groups were included at the same time

From: Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)

  TC HDL TC/HDL LDL TG FRS
Age (b-value, by 1) 0.3 p = 0.09 0.0 P = 0.92 0.0 P = 0.45 0.27 P = 0.10 0.1 P = 0.89
Sex (b-value, F vs M) 6.6 P = 0.10 3.4 P = 0.007 −0.24 P = 0.07 1.7 P = 0.65 2.8 P = 0.77
Diabetes (b-value, Y vs N) −9.7 P = 0.22 0.9 P = 0.68 −0.3 P = 0.24 −7.4 P = 0.34 14.5 P = 0.43
Statins (b-value, Y vs N) −10.1 P = 0.08 −1.3 P = 0.41 −0.0 P = 0.66 −7.8 P = 0.15 1.1 P = 0.93 −0.35 0.62
ART duration (b-value, by 1) −0.2 P = 0.34 −0.1 P = 0.37 − 0.0 P = 0.86 −0.0 P = 0.84 − 0.4 P = 0.52 0.02 P = 0.58
Baseline value (b-value, by 1) − 0.4 P < 0.0001 −0.3 P < 0.0001 − 0.43 P < 0.0001 −0.43 P < 0.0001 − 0.5 p < 0.0001 −0.02 P = 0.32
  1. F female, M male, Y yes, N no, ART antiretroviral therapy